Overview

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Status:
Recruiting
Trial end date:
2025-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb